HFA Icon

Sprout Pharmaceuticals CEO Cindy Whitehead Resigns

HFA Padded
Mani
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Cindy Whitehead, the CEO of Sprout Pharmaceuticals who oversaw the first prescription drug to enhance women’s sexual drive, is quitting just two months after the company was bought by Valeant. According to a statement from Valeant, she will, however, continue to consult with Valeant and Sprout executives after her departure.

Sprout Pharmaceuticals
Sprout Pharmaceuticals

Sprout Pharmaceuticals - Whitehead successfully shepherded Addyi’s launch

Citing concerns about side effects and limited effectiveness, the Food and Drug Administration rejected in 2010 and in 2013 Sprout’s Addyi, often referred to as the “little pink pill.” After the FDA initially rejected Addyi, the pharmaceutical company Boehringer Ingelheim dropped it. However, Ms. Whitehead and...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports